Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.40
+0.30 (3.70%)
At close: Mar 9, 2026, 4:00 PM EDT
8.41
+0.01 (0.12%)
After-hours: Mar 9, 2026, 5:35 PM EDT
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
129
Market Cap
478.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKYTX News
- 4 days ago - Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - GlobeNewsWire
- 6 days ago - Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 6 days ago - Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha
- 13 days ago - Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies - Seeking Alpha